The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

The present invention is related to a method for diagnosing Niemann-Pick disease in a subject comprising a step a), wherein the step a) comprises detecting a biomarker in a sample from the subject.

Provided herein are compounds, compositions, and methods of identifying compounds that neutralize the ability of the cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from agonizing CB1 signaling in peripheral tissues. Further provided herein are methods of treating a disorder associated with dysregulated or abnormal hepatic de novo lipogenesis and/or hepatic selective insulin resistance by inhibiting cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from binding and agonizing CB1.

Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.

An object of the present invention is to make it possible to easily determine a presence or absence of ketosis and/or the possibility of ketosis in an animal on site or the like. Another object of the present invention is to provide an apparatus for performing the determination. A method for determining ketosis according to one embodiment of the present invention includes providing gas detection means with a gas generated from a body fluid collected from an animal (except for humans), and determining ketosis of the animal based on a composition of the gas generated from the body fluid using a response of the gas detection means to the gas generated from the body fluid.

A method for detection or monitoring status of silent brain ischemia (SBI) and cerebrovascular health. The assay reagents and methods described herein provide a specific indicator of cerebral microvascular disease, enabling clinicians to identify patients at risk for the development of SBI. A method of treating a subject having silent brain ischemia and/or metabolic syndrome comprises administering to the subject aspirin therapy, blood pressure therapy, body weight management, and/or a program of diet and exercise when levels of two or more SBI markers are elevated. Described herein are molecules that are produced by cerebral endothelial cells exposed to chronic vascular risk factors including obesity, hyperlipidemia, hypertension, and glucose intolerance. These stress molecules produced by cerebral endothelial cells are detectable in the serum and serve as diagnostic indicators of brain-specific endothelial cell damage and correlate with MRI indicators of silent stroke and impaired cognitive function.

The present disclosure refers to a method for the measurement, diagnosis, treatment, and management of metabolic syndrome comprising the administration of a drug for the treatment of metabolic syndrome and a system for monitoring a drug product to a patient in need thereof, to prevent or reduce the risk of metabolic syndrome and related disorders, by using electronic devices.

Improved methods and systems for diagnosing and for treating Cushing's syndrome and Cushing's Disease are provided herein, including methods and systems for concurrently treating Cushing's syndrome and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome in a patient with an established diagnosis of ACTH-dependent Cushing's syndrome. Treatment methods can use glucocorticoid receptor antagonists (GRAs), which differentially affect the ratio of cortisol to ACTH levels in patients having Cushing's Disease versus patients having Ectopic Cushing's Syndrome. Methods for concurrently treating and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome include obtaining baseline cortisol and ACTH levels of a patient, treating the patient with a GRA according to a protocol that would typically substantially elevate cortisol levels, obtaining post-treatment cortisol and ACTH levels of the patient, determining a differential relationship between baseline cortisol and ACTH levels and post-treatment cortisol and ACTH levels and providing a positive diagnosis based on the differential relationship.

A cell culture comprising a mammalian cell line which is modified to express a heterodimer consisting of a progranulin polypeptide and a prosaposin polypeptide.

The present invention relates to a method for diagnosing a pancreatic function, including: a step of administering a diagnostic agent for a pancreatic function which contains a compound represented by General Formula (1-0) as an active component to a subject; a step of detecting the compound (1-0) accumulated in the pancreas; and a step of quantitatively analyzing an amount of compound (1-0) accumulated in the pancreas.

##STR00001##

[In General Formula (1-0), R represents —O(CH.sub.2).sub.n—, —O(CH.sub.2).sub.nOC.sub.2H.sub.4—, —CH.sub.2O(CH.sub.2).sub.n—, or —CH.sub.2O(CH.sub.2).sub.nOC.sub.2H.sub.4—, n represents an integer of 1 to 5, and Q.sup.1 represents F or —OCH.sub.3].